Cedars-Sinai Medical Center |
Wafa Tawackoli |
Conference - Manage The SPARK Annual Meeting |
2023 CIRM SPARK Research Conference |
$100,000 |
Rampart Bioscience |
Jeffrey Bartlett |
Late Stage Preclinical Projects |
Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia |
$3,999,980 |
Genascence Corporation |
Thomas Chalberg |
Clinical Trial Stage Projects |
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA |
$11,637,194 |
Stanford University |
Joseph Wu |
Conference II |
Stanford Drug Discovery Symposium 2023 |
$50,000 |
University of California, Berkeley |
John Dueber |
Conference II |
BIC 2023 - 23rd Annual UC Systemwide Bioengineering Symposium |
$50,000 |
Stanford University |
Everett Meyer |
Conference II |
Cellular Immune Tolerance Symposium |
$32,751 |
University of California, Davis |
Aijun Wang |
Quest - Discovery Stage Research Projects |
In Utero Treatment of Duchenne Muscular Dystrophy with Non-viral Gene Editing |
$2,035,544 |
University of California, Berkeley |
Fyodor Urnov |
Quest - Discovery Stage Research Projects |
A Treatment for Artemis-deficient Severe Combined Immunodeficiency using Non-Viral CRISPR-driven Safe Harbor Transgenesis in Hematopoietic Stem Cells |
$1,809,372 |
Greenstone Biosciences |
Nikesh Kotecha |
Quest - Discovery Stage Research Projects |
Drug Discovery for Duchenne Muscular Dystrophy Using Patient-Derived Human iPSCs |
$675,000 |
University of California, Los Angeles |
Richard Pietras |
Quest - Discovery Stage Research Projects |
Reversal of dysregulated myelopoiesis in breast cancers and cancer stem cells to boost antitumor immunotherapy |
$2,327,680 |
University of California, Los Angeles |
Song Li |
Quest - Discovery Stage Research Projects |
Vax-CT to promote formation of cancer-specific T memory stem cell for personalized cancer immunotherapy |
$2,267,714 |
Gladstone Institutes, J. David |
Lyandysha Zholudeva |
Quest - Discovery Stage Research Projects |
Excitatory spinal interneurons from human pluripotent stem cells to treat spinal cord injury |
$2,942,198 |
Ossium Health |
Brian Johnstone |
Late Stage Preclinical Projects |
Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease |
$3,457,858 |
City of Hope, Beckman Research Institute |
Jianhua Yu |
Quest - Discovery Stage Research Projects |
Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer |
$2,263,500 |
Ryne Bio |
Howard Federoff |
Late Stage Preclinical Projects |
Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson's disease |
$4,000,000 |
Immusoft Corporation |
Robert Hayes |
Clinical Trial Stage Projects |
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 |
$8,000,000 |
BrainXell Therapeutics |
Matthew Goodus |
Quest - Discovery Stage Research Projects |
Autologous stem cell-derived interneuron cell therapy for spinal cord injury (SCI) |
$2,025,000 |
University of California, Berkeley |
Kevin Healy |
Quest - Discovery Stage Research Projects |
Novel Lipid Nanoparticles for Enhancing eNOS Synthesis for Cardioprotection Post Myocardial Infarction |
$2,060,248 |
Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center |
Michelina Iacovino |
Quest - Discovery Stage Research Projects |
A Novel Therapy for Sanfilippo B |
$2,297,884 |
Cedars-Sinai Medical Center |
Dmitriy Sheyn |
Quest - Discovery Stage Research Projects |
Microgel encapsulated iPSC-derived notochordal cells to treat intervertebral disc degeneration and low back pain |
$2,020,166 |
Scripps Health |
Darryl D’Lima |
Quest - Discovery Stage Research Projects |
Pluripotent Stem Cells for Tendon Tissue Engineering |
$2,734,163 |
University of California, Los Angeles |
Frank Pajonk |
Quest - Discovery Stage Research Projects |
Development of novel small molecules against cancer stem cells in solid cancers |
$2,340,000 |
University of California, Los Angeles |
Gerald Lipshutz |
Quest - Discovery Stage Research Projects |
Gene Therapy for SLC6A8 Creatine Transporter Disorder |
$2,296,920 |
Rubedo Life Sciences Inc. |
Marco Quarta |
Quest - Discovery Stage Research Projects |
Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells. |
$1,450,876 |
The American Society of Gene & Cell Therapy |
Eddie Hopkins |
Conference II |
The American Society of Gene & Cell Therapy: 26th Annual Meeting |
$50,000 |
University of California, Irvine |
Mathew Blurton-Jones |
Conference II |
ALSP Community Conference: Insights and Potential of Cell-Based Therapies for the Treatment of Leukodystrophies |
$42,500 |
University of California, Davis |
Joseph Anderson |
Late Stage Preclinical Projects |
Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease |
$4,048,253 |
Nammi Therapeutics, Inc. |
David Stover |
Late Stage Preclinical Projects |
IND-Enabling activities for the masked immunocytokine, QXL138AM |
$3,999,113 |
Angiocrine Bioscience, Inc. |
Paul Finnegan |
Clinical Trial Stage Projects |
AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205 |
$15,000,000 |
University of California, San Francisco |
Karin Gaensler |
Late Stage Preclinical Projects |
Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells |
$6,000,000 |
Stanford University |
Natalia Gomez-Ospina |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) |
$5,444,353 |
Stanford University |
Alice Bertaina |
Clinical Trial Stage Projects |
Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant |
$11,998,188 |
Tachyon Therapeutics, Inc |
Ivan King |
Clinical Trial Stage Projects |
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers |
$7,141,843 |
University of California, San Diego |
Stephanie Cherqui |
Therapeutic Translational Research Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$4,846,579 |
University of California, Davis |
William Murphy |
Therapeutic Translational Research Projects |
Overcoming resistance to standard CD19-targeted CAR T using a novel triple antigen targeted vector |
$3,869,061 |
Mahzi Therapeutics |
Allyson Berent |
Therapeutic Translational Research Projects |
Development of a Gene Therapy for the Treatment of Pitt Hopkins Syndrome (PHS) - Translating from Animal Proof of Concept to Support Pre-IND Meeting |
$3,800,760 |
City of Hope, Beckman Research Institute |
Jianhua Yu |
Therapeutic Translational Research Projects |
Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α |
$6,036,002 |
Greenstone Biosciences |
Nikesh Kotecha |
Tool Translational Research Projects |
Cell Villages and Clinical Trial in a Dish with Pooled iPSC-CMs for Drug Discovery |
$1,350,000 |
The Biomedical Engineering Society |
Charity Quick |
Conference II |
2023 BMES-CMBE Annual Meeting: "Cell State Transitions in Health, Disease, and Regeneration” |
$22,000 |
Midwinter Conference of Immunologists |
Christel Uittenbogaart |
Conference II |
61st Midwinter Conference of Immunologists |
$48,566 |
Cedars-Sinai Medical Center |
Wafa Tawackoli |
Conference II |
13th Annual California ALS Research Summit |
$50,000 |
International Society for Stem Cell Research |
Chris Barry |
Conference II |
ISSCR Nucleus Forum 2023 |
$25,000 |
University of California, Los Angeles |
Noah Federman |
Alpha Stem Cell Clinics Network Expansion |
Expansion of the Alpha Stem Cell and Gene Therapy Clinic at UCLA |
$8,000,000 |
University of Southern California |
Thomas Buchanan |
Alpha Stem Cell Clinics Network Expansion |
Alpha Clinic Network Expansion for Cell and Gene Therapies |
$7,999,983 |
University of California, Irvine |
Daniela Bota |
Alpha Stem Cell Clinics Network Expansion |
A hub and spoke community model to equitably deliver regenerative medicine therapies to diverse populations across four California counties |
$8,000,000 |
Calidi Biotherapeutics |
Boris Minev |
Late Stage Preclinical Projects |
Allogeneic mesenchymal stem cells loaded with oncolytic virus for cancer treatment |
$3,111,467 |
City of Hope, Beckman Research Institute |
Jana Portnow |
Clinical Trial Stage Projects |
A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas |
$11,999,984 |
Stanford University |
Matthew Porteus |
Alpha Stem Cell Clinics Network Expansion |
The Stanford Alpha Stem Cell Clinic |
$6,920,810 |
University of California, San Francisco |
Mark Walters |
Alpha Stem Cell Clinics Network Expansion |
University of California, San Francisco (UCSF) Alpha Stem Cell Clinic (ASCC) |
$7,994,347 |
Cedars-Sinai Medical Center |
Michael Lewis |
Alpha Stem Cell Clinics Network Expansion |
A comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California |
$7,957,966 |
City of Hope, Beckman Research Institute |
Leo Wang |
Alpha Stem Cell Clinics Network Expansion |
The City of Hope Alpha Clinic: A roadmap for equitable and inclusive access to regenerative medicine therapies for all Californians |
$8,000,000 |
University of California, Davis |
Mehrdad Abedi |
Alpha Stem Cell Clinics Network Expansion |
Alpha Stem Cell Clinic for Northern and Central California |
$7,999,997 |
University of California, San Diego |
Catriona Jamieson |
Alpha Stem Cell Clinics Network Expansion |
UC San Diego Health CIRM Alpha Stem Cell Clinic |
$8,000,000 |
Summit for Stem Cell Foundation |
Melissa King |
Conference II |
Summit Live Continuing Medical Education (CME) Webinar Series: Educating Medical Professionals, Patient Advocates and the Public About Evidence-Based Regenerative Medicine and Stem Cells |
$50,000 |
University of California, Berkeley |
Michael Rape |
Foundation - Discovery Stage Research Projects |
Control of OCT4 abundance and function in human stem cells |
$1,234,023 |
University of California, San Francisco |
Robert Blelloch |
Foundation - Discovery Stage Research Projects |
Development of universal off-the-shelf iPSC derived dendritic cells for use as patient specific anti-tumor vaccine |
$1,391,999 |
University of California, San Diego |
Alexis Komor |
Foundation - Discovery Stage Research Projects |
Development of a stem-cell based approach to interpret global effects of genetic variants contributing to neurodevelopmental disease risk |
$1,518,982 |
University of California, San Diego |
Heidi Cook-Andersen |
Foundation - Discovery Stage Research Projects |
Towards a trophectoderm stem-cell model representing human blastocysts of the highest implantation potential |
$1,584,000 |
Stanford University |
Marius Wernig |
Foundation - Discovery Stage Research Projects |
Developing a microglia replacement therapy |
$1,378,365 |
Greenstone Biosciences |
Syed Ahmed |
Foundation - Discovery Stage Research Projects |
Drug Discovery for Dilated Cardiomyopathy using Patient-Derived Human iPSCs |
$1,350,000 |
Gladstone Institutes, J. David |
Julia Kaye |
Foundation - Discovery Stage Research Projects |
Developing a Human Model of Sporadic ALS Using Machine Learning and Robotic Microscopy |
$1,406,622 |
Excision BioTherapeutics |
William Kennedy |
Clinical Trial Stage Projects |
Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy |
$6,852,486 |
University of California, San Diego |
Francesca Soncin |
Foundation - Discovery Stage Research Projects |
Drivers of trophoblast stem/progenitor cell identity in human placenta |
$993,881 |
University of California, Los Angeles |
Melissa Spencer |
Foundation - Discovery Stage Research Projects |
Engineering AAV capsids for transduction of neural and muscle stem cells |
$999,999 |
University of California, San Francisco |
Harold Chapman |
Foundation - Discovery Stage Research Projects |
Modulation of human alveolar stem cells to promote lung regeneration and avoid pulmonary fibrosis |
$1,626,001 |
University of California, Irvine |
Brian Cummings |
COMPASS Training Grant |
Research Mentorship Program in Regenerative Medicine Careers for a Diverse Undergraduate Student Body |
$2,729,900 |
Cal State Univ, Fullerton |
Alison Miyamoto |
COMPASS Training Grant |
COMPASS: an inclusive Pipeline for Research and Other Stem cell-based Professions in Regenerative medicine (iPROSPR) |
$2,880,800 |
Cal State Univ, San Bernadino |
Daniel Nickerson |
COMPASS Training Grant |
Student Pluripotency: Realizing Untapped Undergraduate Potential in Regenerative Medicine |
$2,909,853 |
The University Corporation at California State University, Northridge |
Cindy Malone |
COMPASS Training Grant |
CSUN CIRM COMPASS Training Program (N-COMPASS) |
$2,777,700 |
California State University San Marcos Corporation |
Bianca Mothe |
COMPASS Training Grant |
COMPASS Program for Southern California Hispanic Serving Institution |
$2,811,200 |
San Francisco State University |
Lily Chen |
COMPASS Training Grant |
Inclusive Pathways for a Stem Cell Scholar (iPSCS) Undergraduate Training Program |
$2,894,500 |
University of California, Merced |
Kara McCloskey |
COMPASS Training Grant |
Training Undergraduates in Stem Cell Engineering and Biology (TUSCEB) |
$2,909,999 |
Cal Poly Corporation, an Auxiliary of California Polytechnic State University, San Luis Obispo |
Kristen Cardinal |
COMPASS Training Grant |
A COMPASS to guide the growth of a diverse regenerative medicine workforce that represents California and benefits the world |
$2,887,939 |
University of California, Santa Barbara |
Dennis Clegg |
COMPASS Training Grant |
Training and mentorship program in stem cell biology and engineering: A COMPASS for the future |
$2,746,000 |
University of California, Los Angeles |
Tracy Johnson |
COMPASS Training Grant |
COMPASS: Accelerating Stem Cell Research by Educating and Empowering New Stem Cell Researchers |
$2,910,000 |
University of California, Berkeley |
John Matsui |
COMPASS Training Grant |
The COMPASS Scholars Program – Developing Today’s Untapped Talent into Tomorrow’s STEM Cell Researchers |
$2,908,950 |
University of Southern California |
Senta Georgia |
COMPASS Training Grant |
USC COMPASS: Guiding Undergraduates to Careers in Regenerative Medicine |
$2,899,999 |
Solano Community College |
James Dekloe |
COMPASS Training Grant |
IDEA-CBMS - Increase Diversity, Equity, and Advancement in Cell Based Manufacturing Sciences |
$2,894,500 |
MiraCosta College |
Michael Fino |
COMPASS Training Grant |
Increase Diversity, Equity, and Advancement in Cell Based Manufacturing Sciences (IDEA-CBMS) |
$2,894,500 |
University of California, Davis |
Alice Tarantal |
COMPASS Training Grant |
COMPASS Undergraduate Program |
$2,909,950 |
The Regents of the University of California on behalf of its Riverside Campus |
Huinan Liu |
COMPASS Training Grant |
Research Training and Mentorship Program to Inspire Diverse Undergraduates toward Regenerative Medicine Careers (RAMP) |
$2,910,000 |
University of California, San Francisco |
Rong Wang |
Conference II |
22nd International Vascular Biology Meeting |
$50,000 |
RARE-X |
Nicole Boice |
Conference II |
RARE-X User's Summit - Patients' Data Powering Progress |
$50,000 |
Cedars-Sinai Medical Center |
Wafa Tawackoli |
Conference II |
Advances in Therapeutic Applications of Stem Cells |
$50,000 |
Wake Forest University Health Sciences |
James Yoo |
Clinical Trial Stage Projects |
Phase I Treatment of Urethral Strictures in Humans |
$3,841,593 |
ImmunoVec |
Ryan Wong |
Late Stage Preclinical Projects |
Hematopoietic Stem Cell Gene Therapy for XCGD |
$3,999,959 |
Nanotools Bioscience |
Alex Savtchenko |
Quest - Discovery Stage Research Projects |
Enabling non-genetic activity-driven maturation of iPSC-derived neurons |
$675,000 |
Minutia, Inc. |
Katy Digovich |
Quest - Discovery Stage Research Projects |
Bioengineering human stem cell-derived beta cell organoids to monitor cell health in real time and improve therapeutic outcomes in patients |
$1,198,550 |
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells |
$1,404,000 |
University of California, Irvine |
Michael Demetriou |
Quest - Discovery Stage Research Projects |
CAR T cells targeting abnormal N-glycans for the treatment of refractory/metastatic solid cancers |
$1,414,800 |
The Scintillon Institute |
Brian Lawson |
Quest - Discovery Stage Research Projects |
An hematopoietic stem-cell-based approach to treat HIV employing CAR T cells and anti-HIV broadly neutralizing antibodies. |
$1,143,600 |
Tenaya Therapeutics, Inc. |
Timothy Hoey |
Quest - Discovery Stage Research Projects |
Cardiac Reprogramming Gene Therapy for Post-Myocardial Infarction Heart Failure |
$1,017,000 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Quest - Discovery Stage Research Projects |
Modified RNA-Based Gene Therapy for Cardiac Regeneration Through Cardiomyocyte Proliferation |
$1,565,784 |
Stanford University |
Judith Shizuru |
Quest - Discovery Stage Research Projects |
Targeted Immunotherapy-Based Blood Stem Cell Transplantation |
$1,341,910 |
University of California, Los Angeles |
Donald Kohn |
Quest - Discovery Stage Research Projects |
Hematopoietic Stem Cell Gene Therapy for Alpha Thalassemia |
$1,177,739 |
University of California, San Diego |
Alysson Muotri |
Quest - Discovery Stage Research Projects |
A treatment for Rett syndrome using glial-restricted neural progenitor cells |
$1,402,240 |
University of California, Los Angeles |
Caroline Kuo |
Quest - Discovery Stage Research Projects |
Defining the Optimal Gene Therapy Approach of Human Hematopoietic Stem Cells for the Treatment of Dedicator of Cytokinesis 8 (DOCK8) Deficiency |
$1,386,232 |
University of California, Davis |
Kyle Fink |
Quest - Discovery Stage Research Projects |
AAV-dCas9 Epigenetic Editing for CDKL5 Deficiency Disorder |
$1,429,378 |
Scripps Research Institute |
Michael Bollong |
Quest - Discovery Stage Research Projects |
Therapeutics to overcome the differentiation roadblock in Myelodysplastic Syndrome (MDS) |
$1,244,160 |
Cedars-Sinai Medical Center |
Robert Barrett |
Quest - Discovery Stage Research Projects |
A new precision medicine based iPSC-derived model to study personalized intestinal fibrosis treatments in pediatric patients with Crohn’s disease |
$776,340 |